Hikma Pharmaceuticals Share Discussion Threads

[suetballs] 22/6/2020 21:41

Exit of major investor - hope this is not a bad omen.
Let's see what the market thinks tomorrow.
Suet

[robertball] 01/6/2020 20:50

Buy on dips?

[cantrememberthis2] 08/5/2020 16:15

Another hidden gem Recovery Play

[drsous] 08/5/2020 15:55

Has anybody received their dividend .Listed payment date 7/5/20 on advfn.

[thewheeliedealer] 07/5/2020 20:35

Hi all,

My mate Peter @Conkers3 and myself did a Twin Petes Investing Podcast a few days ago and part of our discussion covers HIK. We also talked in depth about the current situation in the Markets and how we reckon things could play out. Anyway, if you use Apple or Audioboom you can find it under the 'Conkers Corner' Channel (you want TPI Podcast 22) and you can find it on Soundcloud at the link below.

Ideal listening Lockdown listening !!

Cheers, WD
@wheeliedealer

[suetballs] 02/4/2020 11:59

Yertiz - totally agree.
Wish I had more!
Suet

[yertiz] 02/4/2020 09:51

Safe, solid investment in the current climate. Not too many like Hikma around at present.

[ali47fish] 20/3/2020 07:39

the link shows many companies but not hik

[robertball] 05/3/2020 05:11

Expect this one to hit £30 over next year....

[suetballs] 27/2/2020 09:50

Nice share price rise too.
Suet

[suetballs] 27/2/2020 07:58

Nice 2019 result.
Suet

[itsnotmeitsy0u] 18/12/2019 15:13

lovely rise - passed the 50DMA

[gilesy] 13/12/2019 09:18

bought in today at 18.98
excellent long term prospects

[broadwood] 07/11/2019 11:58

Hikma Pharmaceuticals said it expected revenues in its generics business to be closer to the top end of its guidance range following strong demand and operational improvements.

For the full year, the pharma company said it now expected generics revenue to be closer to the top end of its guidance range of $690m to $720M and continued to expect core operating margin to be in the range of 16% to 18%.

For its injectables business revenue guidance was maintained in the range of $870m to $900m for the full year in 2019 and core operating margin in the range of 36% to 38%.

Its injectables business in the US had experienced good demand, which more than offset increased competition and the gradual decline in revenue from shortages of pain management products, as expected.

Its branded business, meanwhile, benefitted from 'strong growth' in most markets more than offsetting lower sales in Algeria.

'We continue to expect branded revenue growth in constant currency to be in the mid-single digits for the full year in 2019,' the company said.

[robertball] 07/11/2019 10:22

profit taking???

[fhmktg] 29/8/2019 12:04

Any idea when the Advair generic resubmission is expected....time's ticking on.

[red5] 09/8/2019 15:34

lets see if there is a late rally for your 10% rise fingers crossed

[broadwood] 09/8/2019 15:22

019 | 09:14am
- Hikma Pharmaceuticals said it had signed an asset purchase agreement with Insys Therapeutics to acquire a complementary manufacturing platform and two pipeline products.

Hikma acquired unit-dose nasal and sublingual spray manufacturing equipment, as well as two pipeline products, naloxone 505(b)2 nasal spray and epinephrine 505(b)2 nasal spray after Insys was forced to sell its assets after initiating Chapter 11 of the US Bankruptcy Code.

Naloxone is a medication used to block or reverse the effect of opioide, whel epinephrine is a medication used to treat a number of conditions, including anaphylaxis, cardiac arrest, and superficial bleeding.

The announcement comes as the company raised its outlook for its injectables and generics businesses after reporting strong sales in the first half of the year thanks to the launch of new products.

[broadwood] 09/8/2019 08:12

Rocketing. End of day + 10% ??

[broadwood] 09/8/2019 07:52

Hikma Pharmaceuticals upgrades outlook amid 'strong' sales in H1

Just what the doctor ordered.


StockMarketWire.com - Hikma Pharmaceuticals raised its outlook for its injectables and generics businesses after reporting strong sales in the first half of the year thanks to the launch of new products.

The company said it expected full-year Injectables revenue to be in the range of $870m to $900m and core operating margin to be in the range of 36% to 38%.

Generics revenue for the full year was expected to be in the range of $690m to $720m, with core operating margin in the range of 16% to 18%.

Branded revenue, meanwhile, was expected to be higher in the second half of the year and with revenue growth in constant currency to be in the mid-single digits.

The upgraded outlook comes as the company saw profits jumped on the back of an increase in revenues.

For the six months ended 30 June 2019, pre-tax profits rose to $226m from $141m a year earlier and revenue grew 8% to $1,047m, reflecting 'strong sales of our in-market products and new product launches,' the company said.

The interim dividend was raised by 17% to 14 cents per share.

[joshuam] 09/8/2019 07:52

Nice results